|
|
|
| Clinical effect of Clopidogrel combined with Urokinase thrombolysis in the treatment of patients with ST-elevation myocardial infarction |
| XU Guo-wang |
| Department of Cardiology, Gaozhou Hospital of Traditional Chinese Medicine, Guangdong Province, Gaozhou 525200,China |
|
|
|
|
Abstract Objective To explore the clinical effect of Clopidogrel combined with Urokinase thrombolysis in the treatment of patients with ST-elevation myocardial infarction. Methods Fifty patients with ST-segment elevation myocardial infarction treated in our hospital from August 2015 to August 2019 were selected as subjects.By a random number table method, they were divided into the control group (n=25) and the observation group (n=25).Patients in the control group were treated with thrombolytic therapy with Urokinase thrombolysis.Patients in the observation group were treated with Clopidogrel combined with Urokinase thrombolytic therapy.The levels of inflammatory factors, myocardial function indicators, myocardial injury and cardiovascular events were compared between the two groups. Results After treatment, the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and left ventricular end-diastolic dimension(LVEDD) decreased and the level of left ventricular ejection fraction (LVEF) increased, the levels of serum IL-6, TNFα, and LVEDD in the observation group were lower than those of the control group, while LVEF level was higher than that of the control group, and the differences were statistically significant (P＜0.05).After treatment, the levels of cardiac troponin-T (cTnT), creatine kinase-MB (CK-MB), and brain natriuretic peptide (BNP) of patients in the two groups decreased, the levels of cTnT, CK-MB, and BNP in the observation group were lower than those in the control group, with statistically significant differences (P＜0.05).The total incidence of cardiovascular disease in the observation group was lower than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion The application of Clopidogrel combined with Urokinase thrombolysis in patients with ST-segment elevation myocardial infarction can effectively reduce patients′ inflammatory factors and myocardial damage, improve myocardial function, and effectively decrease the incidence of recurrent cardiovascular disease.The therapeutic effect is safe and effective, and it is worth popularizing and applying.
|
|
|
|
|
|
| [1] |
张瑞亮，周红漫.注射用重组人尿激酶原联合氯吡格雷治疗急性ST 段抬高型心肌梗死的临床研究[J].现代药物与临床，2017，32（7）：1221-1224.
|
| [2] |
张春龙，彭绪东.重组人尿激酶原治疗急性ST 段抬高型心肌梗死患者的临床研究[J].心肺血管病杂志，2017，36（6）：436-439.
|
| [3] |
顾磊，李振华，王晓田，等.急性ST 段抬高型心肌梗死尿激酶原溶栓后早期介入与直接介入疗效对比研究[J].中国心血管病研究，2017，15（5）：433-436.
|
| [4] |
张伯亨，张亚静，岳博成，等.尿激酶原联合血栓抽吸对高血栓负荷的STEMI 患者的疗效观察[J].医学研究杂志，2018，47（5）：179-182.
|
| [5] |
牛小伟，张晶晶，白明，等.溶栓药物治疗中国急性ST 段抬高型心肌梗死患者有效性和安全性的网状Meta 分析[J].中国循证医学杂志，2017，17（7）：798-809.
|
| [6] |
李晓华，王佩园，冯宗斌，等.注射用重组人尿激酶原与注射用阿替普酶治疗急性ST 段抬高型心肌梗死的成本-效果分析[J].临床药物治疗杂志，2017，15（4）：35-38.
|
| [7] |
冯六六，刘天华，史骏，等.替格瑞洛与氯吡格雷在急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中应用效果的对比研究[J].实用心脑肺血管病杂志，2018，26（3）：61-64.
|
| [8] |
刘南朝.替格瑞洛与氯吡格雷对急性ST 段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗后预后影响的对比研究[J].实用心脑肺血管病杂志，2018，26（2）：47-50.
|
| [9] |
刁启锋，王飞，王颖颖.溶栓治疗时间对急性ST 段抬高型心肌梗死患者院内MACE 发生率的影响[J].岭南心血管病杂志，2017，23（2）：138-141.
|
| [10] |
迪丽拜尔·阿不力孜，木克热木·阿不力克木，林春梅.心理干预在ST 段抬高型急性心肌梗死患者溶栓治疗中的应用价值[J].贵州医药，2017，41（1）：101-102.
|
| [11] |
王高明.急性ST 段抬高心肌梗死患者合并心力衰竭的危险因素分析[J].当代医学，2017，23（29）：86-88.
|
| [12] |
覃凯.急诊全程优化护理在ST 段抬高心肌梗死患者救治中的应用[J].护理实践与研究，2017，14（2）：62-63.
|
| [13] |
陆超灵，张小新，廖佩娟，等.尿激酶溶栓联合替罗非班或替格瑞洛抗血小板治疗急性ST 段抬高型心肌梗死效果分析[J].河北医学，2017，23（9）：1444-1448.
|
| [14] |
杨亚囡，吴强.替格瑞洛和氯吡格雷对急性ST 段抬高型心肌梗死患者经皮冠状动脉介入术中术后冠脉血流影响[J].现代仪器与医疗，2018，24（1）：29-31.
|
| [15] |
张涛，蓝县武，麦鸿成，等.替格瑞洛与氯吡格雷对急性ST 段抬高型心肌梗死行介入治疗患者安全性及有效性评估的回顾性分析[J].暨南大学学报：自然科学与医学版，2018，39（1）：74-80.
|
|
|
|
